As of Nov 19, 2026, 1 of 1 active firms rate DWTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DWTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.16 – $-0.16 · 1 analysts · +7% YoY
Next period, 1 analysts expect Dogwood Therapeutics, Inc. to earn $-0.16 a share (range $-0.16 – $-0.16), versus $-0.15 a year earlier. Full-year consensus is $-0.78, growing to $-0.63 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $100.0K, rising to $0 next year.
Top analysts covering Dogwood Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DWTX.
#1
Sean Lee
HC Wainwright & Co. · Rank #344
Buy
$12.00+1032.1% to target
Overall win rate
40%
+ Follow
DWTX stock forecast FAQ
What is DWTX's average 12-month price target?+
The 1 active firms with a live target average $12.00 for Dogwood Therapeutics, Inc. over the next 12 months, ranging from a $12.00 high to a $12.00 low, as of Nov 19, 2026.
Is DWTX stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover DWTX?+
1 active firms have a recognized rating on Dogwood Therapeutics, Inc. as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DWTX?+
Among analysts who currently cover DWTX, Sean Lee of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #344). Their current call is Buy with a $12.00 target.
What is Dogwood Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.16 – $-0.16) across 1 analysts. Full-year EPS is projected at $-0.78, rising to $-0.63 the following year.
How much revenue is Dogwood Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $100.0K, growing to $0 next year.
Have analysts been upgrading or downgrading DWTX lately?+
As of Nov 19, 2026, 1 of 1 active firms rate DWTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DWTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.